Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
about
Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7Molecules that target nucleophosmin for cancer treatment: an updateOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2.Emergence of protein kinase CK2 as a key target in cancer therapySynergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cellsCK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.Inhibition of αENaC expression and ENaC activity following blockade of the circadian clock-regulatory kinases CK1δ/ε.Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.Casein kinase: the triple meaning of a misnomer.Casein kinases as potential therapeutic targets.Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB.CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.Therapeutic targeting of CK2 in acute and chronic leukemias.
P2860
Q24304911-CBB4A2E8-1E09-4868-883B-9558EC9F20C1Q26750653-56F140BE-0EC1-4EE9-9CD1-8B048128C25DQ27332192-B60C4265-106A-4792-BEAB-03F291042596Q33894901-5A240DF5-69FE-49CB-B846-E27DF787DAF4Q34046848-71B323C0-A816-4B21-A1EE-04F90AD49FA3Q34265716-EA42C64F-2D45-4924-BE53-AE1C723C14B3Q35577635-CB53DBE2-461A-4909-A80A-D78FDF5BDC59Q36263671-C2535567-98A6-4ECA-A451-43C2C09307C0Q36312671-26791517-8DA5-4EE5-A3ED-63BD207E2941Q37487082-C37F2105-1509-4C35-B5D5-FC24541A4A55Q37641686-5F8CE430-0837-48B8-896A-20E46657CA15Q38211598-C5480FC1-6AAF-4BF4-984F-A35F197D9D11Q38632634-6FF62580-9173-43CA-A6F2-435C78E73A91Q38820266-D5CD2782-9B39-486E-94A1-20795C917CF6Q39511426-550BBC22-C1E8-4AEA-A222-4B415F2D452AQ39652400-9274E9F4-FBC5-42FC-9770-3E07A0D9A3EAQ40108131-6C586FBE-0853-4A61-B412-F28A9AC33AD0Q47677919-2DD32EAF-90C4-45DF-B5D0-D2A05ACEE3ED
P2860
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and preliminary efficac ...... ts with cervical malignancies.
@ast
Safety and preliminary efficac ...... ts with cervical malignancies.
@en
type
label
Safety and preliminary efficac ...... ts with cervical malignancies.
@ast
Safety and preliminary efficac ...... ts with cervical malignancies.
@en
prefLabel
Safety and preliminary efficac ...... ts with cervical malignancies.
@ast
Safety and preliminary efficac ...... ts with cervical malignancies.
@en
P2093
P2860
P356
P1433
P1476
Safety and preliminary efficac ...... ts with cervical malignancies.
@en
P2093
Agueda Santana
Alina Díaz
Ana M Solares
Boris E Acevedo
Carlos A González
Carmen Valenzuela
Dagnelia Castillo
Hugo Sigman
Idania Baladrón
Luis Herrera
P2860
P2888
P356
10.1186/1471-2407-9-146
P407
P577
2009-05-13T00:00:00Z
P5875
P6179
1037338162